Keywords: 
• tuberculosis /
• multi-drug resistance /
• moxifloxacin /
• levofloxacin

Abstract: Objective To compare the clinical effect of moxifloxacin and levofloxacin on treatment of multi-drug resistant pulmonary tuberculosis(TB). Methods From Jan 2011 to Dec 2012, 108 patients who were proved to be multi-drug resistant to tuberculosis in Yuhuan County People's Hospital of Zhejiang Province were included in the study. The patients were divided into moxifloxacin treatment group or levofloxacin treatment group by computer-generated random number and randomly allocated method. The treatment regimens were as follows:in moxifloxacin treatment group, the patients were given moxifloxacin, pasiniazid, pyrazinamide, protionamide, rifapentine, sodium aminosalicylate, and amikacin for 3 months, followed by 6 months treatment of moxifloxacin, pyrazinamide, protionamide, pasiniazid and rifapentine, then moxifloxacin, rifapentine, pyrazinamide, andpasiniazid for 9 months. In levofloxacin treatment group, moxifloxacin was replaced by levofloxacin, and other combinations were same as moxifloxacin group. The treatment time was 18 months in 2 groups. Results At the end of the study, 41 of 53 patients finished the treatment in moxifloxacin-group and 44 of 55 patients finished the treatment in levofloxacin-group. Mortalities were 9.4%(5/53)in moxifloxacin-group and 9.1%(5/55) in levofloxacin-group, respectively. The sputum negative rate was 87.8%(36/41) and 84.1%(37/44) in each group, respectively. The effective rate of chest X ray was 92.7%(38/41) in moxifloxacin group and 93.2%(41/44) in levofloxacin group, and the cavity closure rate were 39%(16/41)and 43.2%(19/44). The rate of serious adverse drug reactions was 13.2%(7/53) and 10.9%(6/55), respectively. There was no significant difference between 2 groups. Conclusion Moxifloxacin combined with other drugs to treat multi-drug-resistant TB had no significant advantages compared to levofloxacin combined with the same drugs.